Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage

Cholestasis of Parenteral Nutrition Clinical Trial

Official title:
A Safer Approach to Total Parenteral Nutrition in Pediatric Short Bowel Syndrome Intended to Decrease the Frequency and Severity of Liver Damage

Status Approved for marketing

Clinical Trial Summary

To provide children dependent on total parenteral nutrition with Omegaven®, a fish oil-based intravenous lipid emulsion that may be less hepatotoxic than conventional, vegetable oil-based intravenous lipid emulsions, and that may therefore reduce the need for liver transplantation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cholestasis
Cholestasis of Parenteral Nutrition
Short Bowel Syndrome

Clinical Trial Details

NCT number	NCT01861834
Study type	Expanded Access
Source	Georgetown University
Contact
Status	Approved for marketing
Phase

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00738101` - Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants	N/A
Completed	`NCT03662282` - Omegaven as Alternative Parenteral Fat Nutrition	Phase 3
Active, not recruiting	`NCT03387579` - Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates	Phase 3
Completed	`NCT02370251` - Compassionate Use of Omegaven in Children	Phase 2/Phase 3
Completed	`NCT01072721` - Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of Study of Pediatric Hepatic Fibrosis	N/A
Recruiting	`NCT05043194` - Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis	N/A